Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

Sara M. Tolaney

Department of Medical Oncology, Dana-Farber Cancer Institute

Zefei Jiang

Department of Breast Cancer, Fifth Medical Center of People’s Liberation Army General Hospital, Beijing

Qingyuan Zhang

Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China

Romualdo Barroso-Sousa

Brasilia Hospital, Rede Américas, Brasilia, Brazil

Yeon Hee Park

Mothaffar F. Rimawi

Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston

Cristina Saura

Vall d’Hebron University Hospital, Barcelona

Andreas Schneeweiss

National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany

Masakazu Toi

Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo

Yee Soo Chae

Department of Oncology and Hematology, Kyungpook National University Chilgok Hospital, Kyungpook National University School of Medicine, Daegu, South Korea

Yasemin Kemal

Department of Medical Oncology, Faculty of Medicine, Altınbas University, Istanbul, Turkey

Mukesh Chaudhari

Department of Medical Oncology, HCG Manavata Cancer Center, Mumbai Naka, Nashik, India

Mehmet A.N. Şendur

Department of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara Bilkent City Hospital, Ankara, Turkey

Toshinari Yamashita

Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan

Monica Casalnuovo

Clinical Oncology Unit, LUCEN, Buenos Aires

Michael A. Danso

Department of Medical Oncology, Brock Cancer Center, Virginia Oncology Associates, Norfolk

Jie Liu

Jagdish Shetty

Late Development Oncology, Clinical Development, Oncology Research and Development, AstraZeneca, Gaithersburg, MD

Pia Herbolsheimer

Late Development Oncology, Clinical Development, Oncology Research and Development, AstraZeneca, Gaithersburg, MD

Sibylle Loibl

Johann Wolfgang Goethe Universität, Frankfurt am Main, Germany